Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 12/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933666 | 0.96 | TGFBR1 (0.45) | TGFBR1HPGDSNPC1WNT3ADYRK1A | |
| SCHEMBL18015360 | 0.93 | HPGDS (0.49) | TGFBR1HPGDSKDRCHEK2PDK2 | |
| SCHEMBL21125087 | 0.91 | HSD17B1 (0.49) | TGFBR1HPGDSKDRCHEK2PDK2 | |
| SCHEMBL21125929 | 0.91 | CHEK2 (0.49) | TGFBR1HPGDSKDRCHEK2PDK2 | |
| SCHEMBL19794441 | 0.90 | HPGDS (0.52) | TGFBR1HPGDSKDRCHEK2PDK2 | |
| SCHEMBL21125828 | 0.90 | CHEK2 (0.49) | TGFBR1HPGDSKDRCHEK2PDK2 | |
| SCHEMBL23956266 | 0.88 | TGFBR1 (0.52) | TGFBR1NPC1LMNAMAPTRAB9A | |
| SCHEMBL21662273 | 0.88 | TGFBR1 (0.52) | TGFBR1NPC1LMNAMAPTRAB9A | |
| SCHEMBL20068613 | 0.88 | CHEK2 (0.48) | TGFBR1HPGDSKDRCHEK2PDK2 | |
| SCHEMBL19933725 | 0.88 | ALDH1A1 (0.44) | TGFBR1HPGDSNPC1WNT3ADYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507294-B1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2021-02-24 | — | — | EP | disclosed |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | MERCK PATENT GMBH | 2021-01-12 | — | — | US | disclosed |
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2019-07-04 | — | — | US | disclosed |
| WO-2018041769-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202851-A1 | BINUCLEAR AND TRINUCLEAR METAL COMPLEXES COMPOSED OF TWO INTER-LINKED TRIPODAL HEXADENTATE LIGANDS FOR USE IN ELECTROLUMINESCENT DEVICES | PARN, PUF60, PARG | TGFBR1 2350/4885HPGDS 4674/4885KDR 1570/4885 |
| US-10889604-B2 | Binuclear and trinuclear metal complexes composed of two inter-linked tripodal hexadentate ligands for use in electroluminescent devices | PARN, PUF60, PARG | TGFBR1 2350/4885HPGDS 4674/4885KDR 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.